There are currently 1011 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Feasibility of a New Model for Exercise Prescription in Cystic Fibrosis
Recruiting
The purpose of this protocol is to begin an exercise program combined with behavioral counseling for patients who are hospitalized with a cystic fibrosis exacerbation. The exercise program will begin during the hospital stay. Beginning an exercise program during this period of reduced mobility and isolation may be an ideal time to deliver a structured exercise prescription along with a behavioral program to promote long-term adherence to exercise (structured physical activity) . Hospitalized pat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/07/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cystic Fibrosis
High Resolution Micro OCT Imaging
Recruiting
The purpose of this study is to learn about using the imaging to make images of the lungs and nose with the long-term goal of the research leading to potential treatments and new therapies for patients with cystic fibrosis.
Gender:
All
Ages:
14 years and above
Trial Updated:
12/06/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis
Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations
Recruiting
Based on previous clinical findings, the investigator hypothesize that ivacaftor will have synergistic effects with drugs that facilitate truncated but partially active W1282X CFTR protein processing (tezacaftor) in patients with W1282X CFTR. In the current study, the investigators propose to directly test the efficacy of tezacaftor/ivacaftor (TEZ/IVA) and Trikafta for W1282X CFTR therapy in the clinic in comparison to ivacaftor alone.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/06/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cystic Fibrosis
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recruiting
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: The Kirklin Clinic of UAB Hospital, Birmingham, Alabama
Conditions: Relapsed or Refractory Acute Myeloid Leukemia
Gout in the ED and Improving Research Participation
Recruiting
The prevalence of gout has been steadily increasing over several decades and is correlated with the rising burden of obesity, chronic cardiac and renal disease; all conditions overrepresented in the Southeastern U.S. - particularly in African Americans. Through a novel emergency department led intervention we aim to improve the care patients with gout receive, both during acute exacerbations and long-term. A secondary goal of the project is to concurrently enhance participation of minorities in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Gout
International (Pediatric) Peritoneal Biobank
Recruiting
Within few years the peritoneal membrane of adult peritoneal dialysis (PD) patients undergoes substantial morphological transformation, including progressive fibrosis, vasculopathy and neoangiogenesis. Ultrafiltration capacity steadily declines and ultimately results in PD failure. In children, peritoneal biopsies demonstrating PD associated alterations have not yet been obtained. They, however, should be particularly informative, since secondary tissue and vascular pathology related to ageing o... Read More
Gender:
All
Ages:
Between 1 day and 90 years
Trial Updated:
12/01/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Kidney Failure, Chronic, Peritoneal Dialysis Complication, Transplantation, Healthy
SIRI Checklist: An Integrated Hospital Model to Optimize HIV Prevention in Persons Who Inject Drugs
Recruiting
The purpose of this study is to develop and test a serious injection-related injections (SIRI) checklist aimed at increasing evidence-based treatment for rural people who use drugs (PWUD) including innovative, long-acting injectable agents. The central hypothesis is that hospital-based care models can successfully engage rural and Southern (PWUD) in effective addiction treatment and infection prevention. The activities in this study will be foundational to Ending the HIV epidemic in rural states... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: HIV Infections, Opioid-Related Disorders, Pre-Exposure Prophylaxis (PrEP)
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Recruiting
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Multiple Myeloma
Trial of Vision Therapy for Intermittent Exotropia
Recruiting
The main objective of this randomized trial comparing vision therapy to observation is to determine the short-term effectiveness of vision therapy on distance intermittent exotropia control. The results will help determine whether to proceed to a full-scale, long-term randomized trial.
Gender:
All
Ages:
Between 8 years and 16 years
Trial Updated:
11/28/2023
Locations: University of Alabama in Birmingham, Birmingham, Alabama
Conditions: Intermittent Exotropia
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Central Research Associates, Birmingham, Alabama
Conditions: Non-Alcoholic Fatty Liver Disease
South-seq: Deoxyribonucleic Acid (DNA) Sequencing for Newborn Nurseries in the South
Recruiting
2,000 infants with signs suggestive of a genetic disorder being treated at a neonatal intensive care unit (NICU) in which African-American and rural populations are highly represented will be enrolled. Whole genome sequencing (WGS) will be used to identify pathogenic variation in DNA from these infants. Stakeholders, including parents, clinicians, and community leaders, will be engaged to develop culturally adapted educational materials and to equip non-genetics providers to return WGS results.... Read More
Gender:
All
Ages:
All
Trial Updated:
11/28/2023
Locations: University of Alabama at Birmingham/Children's of Alabama, Birmingham, Alabama
Conditions: Whole Genome Sequencing
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Recruiting
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (BP) or with Ph+ ALL, who have experienced resistance or intolerance to at least two tyrosine kinase inhibitors (TKIs) or in subjects with Ph+ B-cell precursor (BCP) ALL or lymphoid blast phase CML (CML LBP), who have experienced resistance or intolera... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia